SULT6B1

Across TCGA pan-cancer cohorts, SULT6B1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SULT6B1 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SULT6B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SULT6B1 expression acts as an unfavorable survival marker.

SKCM, SARC, and LUAD are the cancer types where SULT6B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.230	0.781	.004	15	view →
SARC	OS	Median	All	0.183	0.839	<.001	12	view →
LUAD	OS	Median	III,IV	0.228	0.677	.015	12	view →
LIHC	DFS	Median	All	0.096	0.543	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SULT6B1–SKCM (OS)

Open the SKCM breakdown →